Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease

被引:15
|
作者
Alschuler, Lise [1 ,2 ]
Chiasson, Ann Marie [1 ,2 ]
Horwitz, Randy [1 ,2 ]
Sternberg, Esther [1 ,2 ]
Crocker, Robert [1 ,2 ]
Weil, Andrew [2 ,3 ]
Maizes, Victoria [1 ,2 ]
机构
[1] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[2] Andrew Weil Ctr Integrat Med, Tucson, AZ 85711 USA
[3] Univ Arizona, Tucson, AZ 85721 USA
关键词
Integrative medicine; COVID-19; Immune; Diet; Supplements; Osteopathic manipulation; Qigong; Exercise; Stress reduction; Creative expression; Aromatherapy; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; FUNCTIONAL RECEPTOR; PHYSICAL HEALTH; IMMUNE FUNCTION; LUNG-FUNCTION; DOUBLE-BLIND; EXERCISE; QIGONG; SLEEP;
D O I
10.1016/j.explore.2020.12.005
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
The majority of individuals infected with SARS-CoV-2 have mild-to-moderate COVID-19 disease. Convalescence from mild-to-moderate (MtoM) COVID-19 disease may be supported by integrative medicine strategies. Integrative Medicine (IM) is defined as healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. Integrative medicine strategies that may support recovery from MtoM COVID-19 are proposed given their clinically studied effects in related conditions. Adoption of an antiinflammatory diet, supplementation with vitamin D, glutathione, melatonin, Cordyceps, Astragalus and garlic have potential utility. Osteopathic manipulation, Qigong, breathing exercises and aerobic exercise may support pulmonary recovery. Stress reduction, environmental optimization, creative expression and aromatherapy can provide healing support and minimize enduring trauma. These modalities would benefit from clinical trials in people recovering from COVID-19 infection. (c) 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [1] Azithromycin for mild-to-moderate COVID-19
    Hinks, Timothy S. C.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (10): : E100 - E101
  • [2] Considerations for Return to Exercise following Mild-to-Moderate COVID-19 in the Recreational Athlete
    Metzl, Jordan D.
    McElheny, Kathryn
    Robinson, James N.
    Scott, Daphne A.
    Sutton, Karen M.
    Toresdahl, Brett G.
    HSS JOURNAL, 2020, 16 (1_SUPPL) : 102 - 107
  • [3] Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19
    Mueller, Michael
    Volzke, Johann
    Subin, Behnam
    Schmidt, Christian Johann
    Geerdes-Fenge, Hilte
    Reisinger, Emil Christian
    Mueller-Hilke, Brigitte
    VIRUSES-BASEL, 2022, 14 (02):
  • [4] Mild-to-Moderate COVID-19 Infection and Myocarditis: A Review
    Bailey, Eric
    Frishman, William H. H.
    CARDIOLOGY IN REVIEW, 2023, 31 (03) : 173 - 175
  • [5] Features of Mild-to-Moderate COVID-19 Patients With Dysphonia
    Lechien, Jerome R.
    Chiesa-Estomba, Carlos M.
    Cabaraux, Pierre
    Mat, Quentin
    Huet, Kathy
    Harmegnies, Bernard
    Horoi, Mihaela
    Le Bon, Serge Daniel
    Rodriguez, Alexandra
    Dequanter, Didier
    Hans, Stephane
    Crevier-Buchman, Lise
    Hochet, Baptiste
    Distinguin, Lea
    Chekkoury-Idrissi, Younes
    Circiu, Marta
    El Afia, Fahd
    Barillari, Maria Rosaria
    Cammaroto, Giovanni
    Fakhry, Nicolas
    Michel, Justin
    Radulesco, Thomas
    Martiny, Delphine
    Lavigne, Philippe
    Jouffe, Lionel
    Descamps, Geraldine
    Journe, Fabrice
    Trecca, Eleonora M. C.
    Hsieh, Julien
    Delgado, Irene Lopez
    Calvo-Henriquez, Christian
    Vergez, Sebastien
    Khalife, Mohamad
    Molteni, Gabriele
    Mannelli, Giuditta
    Cantarella, Giovanna
    Tucciarone, Manuel
    Souchay, Christel
    Leich, Pierre
    Ayad, Tareck
    Saussez, Sven
    JOURNAL OF VOICE, 2022, 36 (02) : 249 - 255
  • [6] Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
    Cavalcanti, A. B.
    Zampieri, F. G.
    Rosa, R. G.
    Azevedo, L. C. P.
    Veiga, V. C.
    Avezum, A.
    Damiani, L. P.
    Marcadenti, A.
    Kawano-Dourado, L.
    Lisboa, T.
    Junqueira, D. L. M.
    de Barros e Silva, P. G. M.
    Tramujas, L.
    Abreu-Silva, E. O.
    Laranjeira, L. N.
    Soares, A. T.
    Echenique, L. S.
    Pereira, A. J.
    Freitas, F. G. R.
    Gebara, O. C. E.
    Dantas, V. C. S.
    Furtado, R. H. M.
    Milan, E. P.
    Golin, N. A.
    Cardoso, F. F.
    Maia, I. S.
    Hoffmann Filho, C. R.
    Kormann, A. P. M.
    Amazonas, R. B.
    Bocchi de Oliveira, M. F.
    Serpa-Neto, A.
    Falavigna, M.
    Lopes, R. D.
    Machado, F. R.
    Berwanger, O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21): : 2041 - 2052
  • [7] Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design
    Destache, Christopher J.
    Aurit, Sarah J.
    Schmidt, David
    Erkes, Laura Peet
    Tierney, Maureen
    Vivekanandan, Renuga
    PHARMACOTHERAPY, 2021, 41 (09): : 743 - 747
  • [8] Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Moser, Carlee B.
    Li, Jonathan Z.
    Hughes, Michael D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (16): : 1533 - 1535
  • [9] Mild-to-Moderate Croup Presentations in Patients With COVID-19 Infection
    Mathew, Danica
    Calderon, Jose Cucalon
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [10] Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
    Cao, Bin
    Wang, Yeming
    Lu, Hongzhou
    Huang, Chaolin
    Yang, Yumei
    Shang, Lianhan
    Chen, Zhu
    Jiang, Rongmeng
    Liu, Yihe
    Lin, Ling
    Peng, Ping
    Wang, Fuxiang
    Gong, Fengyun
    Hu, Honglin
    Cheng, Cong
    Yao, Xiangyang
    Ye, Xianwei
    Zhou, Hourong
    Shen, Yinzhong
    Liu, Chenfan
    Wang, Chunying
    Yi, Zhennan
    Hu, Bijie
    Xu, Jiuyang
    Gu, Xiaoying
    Shen, Jingshan
    Xu, Yechun
    Zhang, Leike
    Fan, Jia
    Tang, Renhong
    Wang, Chen
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (03): : 230 - 241